BeOne Medicines (NASDAQ:ONC – Get Free Report) and Sunshine Biopharma (NASDAQ:SBFM – Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings.
Profitability
This table compares BeOne Medicines and Sunshine Biopharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| BeOne Medicines | 10.70% | 14.23% | 7.82% |
| Sunshine Biopharma | -17.94% | -26.36% | -20.60% |
Insider & Institutional Ownership
48.5% of BeOne Medicines shares are owned by institutional investors. Comparatively, 42.0% of Sunshine Biopharma shares are owned by institutional investors. 6.2% of BeOne Medicines shares are owned by insiders. Comparatively, 0.5% of Sunshine Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| BeOne Medicines | $6.13 billion | 6.21 | $286.93 million | $5.68 | 61.01 |
| Sunshine Biopharma | $35.35 million | 0.12 | -$5.97 million | ($10.15) | -0.10 |
BeOne Medicines has higher revenue and earnings than Sunshine Biopharma. Sunshine Biopharma is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
BeOne Medicines has a beta of 0.51, suggesting that its stock price is 49% less volatile than the S&P 500. Comparatively, Sunshine Biopharma has a beta of 1.17, suggesting that its stock price is 17% more volatile than the S&P 500.
Analyst Recommendations
This is a summary of current ratings and recommmendations for BeOne Medicines and Sunshine Biopharma, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| BeOne Medicines | 1 | 1 | 12 | 3 | 3.00 |
| Sunshine Biopharma | 1 | 1 | 1 | 0 | 2.00 |
BeOne Medicines currently has a consensus price target of $402.71, suggesting a potential upside of 16.22%. Sunshine Biopharma has a consensus price target of $70.00, suggesting a potential upside of 6,503.77%. Given Sunshine Biopharma’s higher possible upside, analysts plainly believe Sunshine Biopharma is more favorable than BeOne Medicines.
Summary
BeOne Medicines beats Sunshine Biopharma on 13 of the 15 factors compared between the two stocks.
About BeOne Medicines
BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.
About Sunshine Biopharma
Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine Biopharma, Inc. is headquartered in New York, New York.
Receive News & Ratings for BeOne Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeOne Medicines and related companies with MarketBeat.com's FREE daily email newsletter.
